FTC & PBMs: So What?
Executive Summary
The FTC's August announcement of its settlement agreement with Merck/Medco Managed care outlined rules governing the PBM's relationaship with Merck & Co. Inc. The FTC's aggressive tone--which suggested that Medco acknowledged that past actions in promoting Merck drugs restricted competition and resulted in higher prices for some drugs--made the agreement seem like a victory for the FTC and upset Medco officials who concede no such things.
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.